{"id":15907,"date":"2026-08-31T18:40:24","date_gmt":"2026-08-31T18:40:24","guid":{"rendered":"https:\/\/qiccl.com\/?post_type=opportunity&#038;p=15907"},"modified":"2026-09-01T12:12:57","modified_gmt":"2026-09-01T12:12:57","slug":"production-of-acyclovir-active-pharmaceutical-ingredient","status":"publish","type":"opportunity","link":"https:\/\/qiccl.com\/en\/opportunities\/production-of-acyclovir-active-pharmaceutical-ingredient\/","title":{"rendered":"Production of Acyclovir Active Pharmaceutical Ingredient"},"content":{"rendered":"\n<table id=\"tablepress-249\" class=\"tablepress tablepress-id-249\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">Title<\/th><th class=\"column-2\">General Information<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Project Title<\/td><td class=\"column-2\">Production of Acyclovir Active Pharmaceutical Ingredient<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Project Capacity<\/td><td class=\"column-2\">21,428 kg\/year<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Employment<\/td><td class=\"column-2\">18 Employees<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Product Application<\/td><td class=\"column-2\">Active pharmaceutical ingredient used in the production of antiviral medicines for the treatment of herpes virus infections, including herpes simplex and herpes zoster<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Industry Type<\/td><td class=\"column-2\">Healthcare &amp; Pharmaceuticals<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-249 from cache -->\n\n\n<table id=\"tablepress-250\" class=\"tablepress tablepress-id-250\">\n<thead>\n<tr class=\"row-1\">\n\t<th class=\"column-1\">KEY INVESTMENT INDICATORS<\/th><th class=\"column-2\">COST(USD)<\/th>\n<\/tr>\n<\/thead>\n<tbody class=\"row-striping row-hover\">\n<tr class=\"row-2\">\n\t<td class=\"column-1\">Fixed Investment  Cost<\/td><td class=\"column-2\">357,100<\/td>\n<\/tr>\n<tr class=\"row-3\">\n\t<td class=\"column-1\">Working Capital<\/td><td class=\"column-2\">53,397<\/td>\n<\/tr>\n<tr class=\"row-4\">\n\t<td class=\"column-1\">Total Investment Cost<\/td><td class=\"column-2\">410,497<\/td>\n<\/tr>\n<tr class=\"row-5\">\n\t<td class=\"column-1\">Annual Sales<\/td><td class=\"column-2\">532,244<\/td>\n<\/tr>\n<tr class=\"row-6\">\n\t<td class=\"column-1\">Internal Rate of Return (IRR)<\/td><td class=\"column-2\">26.89%<\/td>\n<\/tr>\n<tr class=\"row-7\">\n\t<td class=\"column-1\">Investment Return Period<\/td><td class=\"column-2\">4.88<\/td>\n<\/tr>\n<tr class=\"row-8\">\n\t<td class=\"column-1\">Implementation Period<\/td><td class=\"column-2\">12months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<!-- #tablepress-250 from cache -->","protected":false},"excerpt":{"rendered":"TitleGeneral Information Project TitleProduction of Acyclovir Active Pharmaceutical Ingredient Project Capacity21,428 kg\/year Employment18 Employees Product ApplicationActive pharmaceutical ingredient used in the production of antiviral medicines for the treatment of herpes virus infections, including herpes simplex and herpes zoster Industry TypeHealthcare &amp; Pharmaceuticals KEY INVESTMENT INDICATORSCOST(USD) Fixed Investment Cost357,100 Working Capital53,397 Total Investment Cost410,497 Annual Sales532,244 [...]","protected":false},"featured_media":16174,"template":"","meta":{"opportunity_investment":410497,"opportunity_expected_return":26.89,"footnotes":""},"opportunity_category":[194],"class_list":["post-15907","opportunity","type-opportunity","status-publish","has-post-thumbnail","hentry","opportunity_category-healthcare-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/qiccl.com\/en\/wp-json\/wp\/v2\/opportunity\/15907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/qiccl.com\/en\/wp-json\/wp\/v2\/opportunity"}],"about":[{"href":"https:\/\/qiccl.com\/en\/wp-json\/wp\/v2\/types\/opportunity"}],"version-history":[{"count":1,"href":"https:\/\/qiccl.com\/en\/wp-json\/wp\/v2\/opportunity\/15907\/revisions"}],"predecessor-version":[{"id":15912,"href":"https:\/\/qiccl.com\/en\/wp-json\/wp\/v2\/opportunity\/15907\/revisions\/15912"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/qiccl.com\/en\/wp-json\/wp\/v2\/media\/16174"}],"wp:attachment":[{"href":"https:\/\/qiccl.com\/en\/wp-json\/wp\/v2\/media?parent=15907"}],"wp:term":[{"taxonomy":"opportunity_category","embeddable":true,"href":"https:\/\/qiccl.com\/en\/wp-json\/wp\/v2\/opportunity_category?post=15907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}